Customer support

xie@china-sinoway.com
English
banner
Products
Home

API

Ticagrelor 274693-27-5

Ticagrelor 274693-27-5

99% up by HPLC
  • Product Details

Product Information


Product name

Ticagrelor

CAS No.

274693-27-5

Molecular Formula

C23H28F2N6O4S

Molecular Weight

522.576

Quality Standard

99% up by HPLC

Appearance

White to off-white powder


COA of Ticagrelor


ITEMS

SPECIFICATION

RESULTS

Appearance

White to off-white powder

Conforms

Optical rotation

-50~ 60

-53

Identification

IR

Conforms

HPLC

Conforms

Isomers

TGD10.15%

Undetected

TGD20.15%

Undetected

TGE0.15%

Undetected

TG-160.15%

Undetected

Related substance

De-ethoxyl of TG 0.15%

0.01%

Any single impurity 0.1%

0.05%

Total impurities 1.0%

0.10%

Residue on ignition

0.1%

0.08%

Loss on drying

0.5%

0.14%

Residual solvent

Ethyl ether <5000ppm

Acetone<5000ppm

Dichloromethane <600ppm

Ethyl acetate <5000ppm

Triethylamine <320ppm

Toluene<890ppm

Tetrahydrofuran <720ppm

Methanol<3000ppm

Ethanol<5000ppm

Acetonitrile<4 10ppm

hexane <290ppm

N-methyl pyrrolidone<530ppm

Undetected

Undetected

Undetected

73 ppm

Undetected

Undetected

Undetected

Undetected

Undetected

Undetected

Undetected

Undetected

Assay

99%-102%

100.5%

Conclusion

The result conforms to the enterprise standards.


Usage


Function of Ticagrelor

Today, with the continuous increase of acute coronary syndrome (ACS), antiplatelet therapy is still one of the important treatment measures for ACS. Ticagrelor is a novel cyclopentyltriazole pyrimidine (CPTP) oral antiplatelet drug with ATC code B01AC24. Ticagrelor is a non-prodrug that can act directly without hepatic metabolic activation, and binds reversibly to the P2Y12 ADP receptor. The results of the PLATO study showed that ticagrelor treatment for 12 months, without increasing major bleeding, further significantly reduced the risk of cardiovascular death/myocardial infarction/stroke composite endpoint events in ACS patients by 16%, and significantly Reduce cardiovascular death by 21%. The clinical efficacy and safety of ticagrelor have been validated and supported by the Platelet Inhibition and Patient Outcomes Outcomes Study (PLATO Study) and its multiple subgroups. Based on the benefits of ticagrelor treatment for ACS patients, guidelines in many countries state that ticagrelor is listed as the first-line recommendation. In the two authoritative guidelines of the European Society of Cardiology (ESC NSTE-ACS guidelines in 2011 and STEMI guidelines in 2012), it is pointed out that the use of clopidogrel in patients who cannot receive ticagrelor therapy is sufficient. Shows approval for the new drug to further reduce mortality.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Mupirocin powder
MUPIROCIN 12650-69-0
99% up / GMP
IMATINIB MESYLATE
IMATINIB MESYLATE 220127-57-1
In-house Standard
CEFTIOFUR SODIUM
CEFTIOFUR SODIUM 104010-37-9
In-house Specification
OSELTAMIVIR PHOSPHATE
OSELTAMIVIR PHOSPHATE 204255-11-8
99% up , Pharmaceutical Grade
THYMOPENTIN
THYMOPENTIN 69558-55-0
99% up Medical Grade
LOSARTAN POTASSIUM
LOSARTAN POTASSIUM 124750-99-8
98.5% up, USP32 
AZILSARTAN
AZILSARTAN 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact